Results 51 to 60 of about 20,887 (223)

The MYCN Oncogene [PDF]

, 2013
MYCN is a member of the MYC family of oncogenes, which also includes c-MYC and MYCL. Despite knowing about the existence of MYCN for nearly thirty years, the majority of functional studies involving MYC family members have focused on c-MYC due to the limited expression profile of MYCN in human cancers, and also in part due to the existence of highly ...
Leanna Cheung, Jayne E., Michelle Haber, Murray D.   +3 more
openaire   +1 more source

PGV-1 Causes Disarrangement of Spindle Microtubule Organization Resulting in Aberrant Mitosis in HLF and HuH6 Cells Associated with Altered MYCN Status [PDF]

Advanced Pharmaceutical Bulletin
Purpose: The HLF and HuH-6 cell lines represent hepatocellular carcinoma (HCC) with different characteristics in chromosome content that may give different drug responses. Here, PGV-1 was intended to challenge the growth-suppressing effect on HLF and HuH-
Nadzifa Nugraheni, Ummi Maryam Zulfin, Beni Lestari, Novia Permata Hapsari, Muthi Ikawati, Rohmad Yudi Utomo, Yusuke Suenaga, Yoshitaka Hippo, Edy Meiyanto   +8 more
doaj   +1 more source

Inhibition of OCT4 binding at the MYCN locus induces neuroblastoma cell death accompanied by downregulation of transcripts with high-open reading frame dominance

Frontiers in Oncology
Amplification of MYCN is observed in high-risk neuroblastomas (NBs) and is associated with a poor prognosis. MYCN expression is directly regulated by multiple transcription factors, including OCT4, MYCN, CTCF, and p53 in NB.
Kazuma Nakatani, Kazuma Nakatani, Kazuma Nakatani, Kazuma Nakatani, Hiroyuki Kogashi, Hiroyuki Kogashi, Takanori Miyamoto, Taiki Setoguchi, Tetsushi Sakuma, Kazuto Kugou, Yoshinori Hasegawa, Takashi Yamamoto, Yoshitaka Hippo, Yoshitaka Hippo, Yoshitaka Hippo, Yusuke Suenaga   +15 more
doaj   +1 more source

CD133 expression and amplification induce chemoresistance and reduce average survival time in pediatric neuroblastoma

Journal of International Medical Research, 2018
Objectives Neuroblastoma (NB) is the most common pediatric solid tumor derived from the sympathetic nervous system. MYCN is amplified in nearly half of patients with NB, and its association with rapid disease progression and poor outcome is controversial.
Zhi-Yong Zhong, Bao-Jun Shi, Hui Zhou, Wen-Bo Wang   +3 more
doaj   +1 more source

Organoids in pediatric cancer research

FEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

Biological effects of induced MYCN hyper-expression in MYCN-amplified neuroblastomas

International Journal of Oncology, 2010
Neuroblastoma is a childhood malignancy of the sympathetic nervous system. The tumor exhibits two different phenotypes: favorable and unfavorable. MYCN amplification is associated with rapid tumor progression and the worst neuroblastoma disease outcome.
Jaime, Torres, Paul L, Regan, Robby, Edo, Payton, Leonhardt, Eric I, Jeng, Eric F, Rappaport, Naohiko, Ikegaki, Xao X, Tang   +7 more
openaire   +3 more sources

Adult Pulmonary Blastoma: A Case Report with Spectrum of Rare Manifestations [PDF]

Türk Patoloji Dergisi
Pulmonary blastoma (PB) is an exceedingly rare and aggressive malignant lung neoplasm that has distinct biphasic morphology. In this report, we document rare manifestations and molecular alterations in PB.
Mayur PARKHI, Nishtha AHUJA, Divyesh KUMAR, Rajender Kumar BASHER, Navneet SINGH, Harkant SINGH, Amanjit BAL   +6 more
doaj   +1 more source

Prognostic significance of MYCN related genes in pediatric neuroblastoma: a study based on TARGET and GEO datasets

BMC Pediatrics, 2020
Background Neuroblastoma patients with MYCN amplification are associated with poor prognosis. However, the prognostic relevance of MYCN associated genes in neuroblastoma is unclear. Methods The expression profiles of MYCN associated genes were identified
Haiwei Wang, Xinrui Wang, Liangpu Xu, Ji Zhang, Hua Cao   +4 more
doaj   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

Metastasis in neuroblastoma: the MYCN question

Frontiers in Oncology, 2023
Oncogenic drivers like MYCN in neuroblastoma subsets continues to present a significant challenge owing to its strong correlation with high-risk metastatic disease and poor prognosis. However, only a limited number of MYCN-regulatory proteins associated with tumor initiation and progression have been elucidated.
openaire   +4 more sources